PDF
File
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Stockholm, February 22, 2024 - The board of directors in Intervacc AB (publ) has decided to change the date for the publication of the interim report for the first quarter of 2024 to May 15, 2024, previously communicated as May 23. The board has also decided to change the date of the annual general meeting to May 15, 2024, previously communicated as June 12, 2024.
For more information please contact:
Jonas Sohlman, CEO
Phone: +46 (0)8 120 10 600, Cell: +46 (0) 70 576 30 73
E-mail: jonas.sohlman@intervacc.se
The information was submitted for publication, through the agency of the contact person set out above on February 22, 2024, 14.30 p.m. CET.
About Intervacc
Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Sciences where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: adviser@eminova.se,Phone: +46 (0)8 - 684 211 10